Recombinant Human KIR2DL3/CD158b2 Fc Chimera Protein, CF

Catalog # Availability Size / Price Qty
2014-KR-050
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (4)
FAQs
Supplemental Products
Reviews (2)

Recombinant Human KIR2DL3/CD158b2 Fc Chimera Protein, CF Summary

Product Specifications

Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to bind HEK293T human embryonic kidney cells in a flow cytometry assay. When 10 μg of Recombinant Human KIR2DL3/CD158b2 Fc Chimera is added to 5 x 105 HEK293T cells, >20% of the cells will bind to the protein.
Source
Mouse myeloma cell line, NS0-derived human KIR2DL3/CD158b2 protein
Human KIR2DL3
(His22-His245)
Accession # P43628
IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus
Accession #
N-terminal Sequence
Analysis
His22
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
51.2 kDa (monomer)
SDS-PAGE
66-75 kDa, reducing conditions

Product Datasheets

You must select a language.

x

2014-KR

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

2014-KR

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: KIR2DL3/CD158b2

KIR2DL3 (2DL3, formerly NKAT2, designated CD158b2) is a 341 amino acid (aa) type I transmembrane glycoprotein that belongs to the human killer cell Ig‑like receptor (KIR) family of molecules (1, 2). KIRs are expressed on human CD56dim NK cells and T cell subsets, and regulate effector functions in the innate immune system (1-3). KIRs are named for the number of Ig‑like domains (2D or 3D) in the extracellular domain (ECD), and whether they have long or short (L, S) cytoplasmic tails (1‑3). Individuals will express varying subsets of inhibiting and activating KIRs with varying polymorphisms (1, 4). Like other inhibiting KIRs, KIR2DL3 has two ITIM domains within its long tail that block activating receptor clustering (2). Within the ECD, KIR2DL3 shares very high aa sequence identity (98%) with KIR2DL2. The two segregate as alleles of the same gene; both recognize Asn80‑containing HLA‑C1 and, more weakly, Lys80‑containing C2 allotypes (1, 5). Extracellular aa identity is also high for KIR2DL1 (93%). The three molecules together recognize and inhibit NK cytotoxicity against cells expressing any HLA‑C allotype, allowing for self‑recognition (1‑3). Compared with KIR2DL2, KIR2DL3 shows lower avidity for HLA‑C1 ligands; when compared to KIR2DL1, KIR2DL3 has lower avidity but broader specificity for HLA-C1 ligands (1, 5, 6). Configurations of inhibiting and activating KIR can alter an individual’s susceptibility to viral and autoimmune diseases and leukemia (1‑3). For example, rheumatoid arthritis patients that are positive for KIR2DL3 and negative for KIR2DS3 have an earlier disease diagnosis (7).

References
  1. Purdy, A.K. and Campbell, K.S. (2009) Cancer Biol. Ther. 8:13.
  2. Lanier, L. L. (2005) Annu. Rev. Immunol. 23:225.
  3. Kulkarni, S. et al. (2008) Semin. Immunol. 20:343.
  4. Middleton, D. and F. Gonzelez (2009) Immunology 129:8.
  5. Moesta, A.K. et al. (2008) J. Immunol. 180:3969.
  6. Hilton, H.G. et al. (2012) J. Immunol. 189:1418.
  7. Majorczyk, E. et al. (2007) Genes Immun. 8:678.
Long Name
Killer Cell Immunoglobulin-like Receptor, Two Domain Long Cytoplasmic Tail, 3
Entrez Gene IDs
3804 (Human)
Alternate Names
CD158 antigen-like family member B2; CD158b2 antigen; CD158b2; CD158B2CD158b; cl-6; killer cell immunoglobulin-like receptor 2DL3; killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3; Killer inhibitory receptor cl 2-3; KIR-023GB; KIR2DL3; KIRCL23; KIR-K7b; KIR-K7c; MGC129943; MHC class I NK cell receptor; natural killer associated transcript 2; natural killer cell inhibitory receptor KIR2DL3; Natural killer-associated transcript 2; NKAT; NKAT2; NKAT-2; NKAT2A; nkat2b; NKAT2GL183; NK-receptor; p58 natural killer cell receptor clone CL-6; p58 NK receptor CL-6; p58; p58.2 MHC class-I specific NK receptor; p58.2 MHC class-I-specific NK receptor

Citations for Recombinant Human KIR2DL3/CD158b2 Fc Chimera Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

4 Citations: Showing 1 - 4
Filter your results:

Filter by:

  1. HIV-1 Nef-mediated downregulation of CD155 results in viral restriction by KIR2DL5+ NK cells
    Authors: P Fittje, A Hœlzemer, WF Garcia-Bel, S Vollmers, A Niehrs, K Hagemann, G Martrus, C Körner, F Kirchhoff, D Sauter, M Altfeld
    Oncogene, 2022-06-24;18(6):e1010572.
    Species: Human
    Sample Types: Recombinant Proteins
    Applications: Bioassay
  2. The Activating Human NK Cell Receptor KIR2DS2 Recognizes a ?2-Microglobulin-Independent Ligand on Cancer Cells
    Authors: L Thiruchelv, SE Hoelsbrekk, PC Saether, E Gyllensten, D Pende, S Fossum, MR Daws, E Dissen
    J. Immunol, 2017-02-15;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Binding Assay
  3. ERAP1 regulates natural killer cell function by controlling the engagement of inhibitory receptors.
    Authors: Cifaldi L, Romania P, Falco M, Lorenzi S, Meazza R, Petrini S, Andreani M, Pende D, Locatelli F, Fruci D
    Cancer Res, 2015-01-15;75(5):824-34.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Peptide selectivity discriminates NK cells from KIR2DL2- and KIR2DL3-positive individuals.
    Authors: Cassidy S, Mukherjee S, Myint T, Mbiribindi B, North H, Traherne J, Mulder A, Claas F, Purbhoo M, Das J, Khakoo S
    Eur J Immunol, 2014-11-29;45(2):492-500.
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs
Loading...

Reviews for Recombinant Human KIR2DL3/CD158b2 Fc Chimera Protein, CF

Average Rating: 4 (Based on 2 Reviews)

5 Star
0%
4 Star
100%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Recombinant Human KIR2DL3/CD158b2 Fc Chimera Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human KIR2DL3/CD158b2 Fc Chimera Protein, CF
By Sivanesan Dakshanamurthy on 12/06/2018
Application: SPR assay
Reason for Rating: good quality

Recombinant Human KIR2DL3/CD158b2 Fc Chimera Protein, CF
By Sivanesan Dakshanamurthy on 11/30/2018
Application: Binding assay/Protein-protein interaction